Interleukin-31 monoclonal antibody

• US 8,790,651 B2
• Filed: 06/28/2012
• Issued: 07/29/2014
• Est. Priority Date: 07/21/2011
• Status: Active Grant

• Current Assignee: Zoetis Services LLC (Zoetis Incorporated)
• Original Assignee: ZOETIS LLC (Zoetis Incorporated)
• Inventors: Bammert, Gary F., Dunham, Steven A.
• Primary Examiner(s): KEMMERER, ELIZABETH
• Application Number:
  US13/536,081
• Publication Number:
  US 20130022616A1
• Time in Patent Office: 761 Days
• Field of Search: None
• US Class Current: 424/145.1
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 2039/54 characterised by the route of administration
• CPC Class Codes: A61K 2039/552 Veterinary vaccine
• CPC Class Codes: A61K 2039/55527 Interleukins
• CPC Class Codes: A61K 39/395 Antibodies agglutinins A61K38/36 ; as drug carriers A61K47/50; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
• CPC Class Codes: A61K 39/39533 against materials from animals
• CPC Class Codes: A61K 39/3955 against proteinaceous materials, e.g. enzymes, hormones, lymphokines
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61P 17/04 Antipruritics
• CPC Class Codes: A61P 17/06 Antipsoriatics
• CPC Class Codes: A61P 17/08 Antiseborrheics
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 37/06 Immunosuppressants, e.g. drugs for graft rejection
• CPC Class Codes: A61P 37/08 Antiallergic agents antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07K 16/244 Interleukins [IL]
• CPC Class Codes: C07K 2317/24 containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
• CPC Class Codes: C07K 2317/33 Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
• CPC Class Codes: C07K 2317/34 Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
• CPC Class Codes: C07K 2317/76 : Antagonist effect on antigen, e.g. neutralization or inhibition of binding
• CPC Class Codes: C07K 2317/92 : Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
• CPC Class Codes: G01N 2333/54 : Interleukins [IL]
• CPC Class Codes: G01N 33/6869 : Interleukin

Abstract

An isolated antibody that specifically binds to at least one of canine Interleukin-31 (IL-31) or feline IL-31 is provided. Such antibodies can be in the form of diagnostic and/or veterinary compositions useful for treating a pruritic and/or allergic condition in dogs or cats.

Claims

1. An isolated antibody, or antigen-binding portion thereof comprising at least one of the following combinations of complementary determining region (CDR) sequences:

1) 11E12;

variable heavy (VH)-CDR1 of SEQ ID NO;

1, VH-CDR2 of SEQ ID NO;

4, VH-CDR3 of SEQ ID NO;

7, variable light (VL)-CDR1 of SEQ ID NO;

10, VL-CDR2 of SEQ ID NO;

13, and VL-CDR3 of SEQ ID NO;

16;

2) 19D07;

VH-CDR1 of SEQ ID NO;

2, VH-CDR2 of SEQ ID NO;

5, VH-CDR3 of SEQ ID NO;

8, VL-CDR1 of SEQ ID NO;

11, VL-CDR2 of SEQ ID NO;

14, and VL-CDR3 of SEQ ID NO 17;

or

3) 34D03;

VH-CDR1 of SEQ ID NO;

3, VH-CDR2 of SEQ ID NO;

6, VH-CDR3 of SEQ ID NO;

9, VL-CDR1 of SEQ ID NO;

12, VL-CDR2 of SEQ ID NO;

15, and VL-CDR3 of SEQ ID NO;

18.

2. The antibody of claim 1, wherein said antibody reduces, inhibits, or neutralizes an IL-31-mediated pruritic or allergic condition.

3. The antibody of claim 1, wherein said antibody is a monoclonal antibody.

4. The antibody of claim 3, wherein the antibody is chimeric.

5. The antibody of claim 3, wherein the antibody is caninized or felinized.

6. The antibody of claim 1, wherein said antibody reduces, inhibits, or neutralizes IL-31 activity in a dog or cat.

7. The antibody of claim 1 comprising at least one of the group consisting of:

a) a variable light chain comprising

8. A veterinary composition comprising a therapeutically effective amount of the antibody of claim 1.

9. A monoclonal antibody that specifically binds to a region between about amino acid residues 95 and 125 of the canine IL-31 amino acid sequence of SEQ ID NO:

32 or a corresponding region in feline IL-31.

10. The antibody of claim 9, wherein the antibody specifically binds to a region between about amino acid residues 102 and 122 of the canine IL-31 sequence of SEQ ID NO:

32 or a corresponding region in feline IL-31.

11. The antibody of claim 9, wherein the antibody specifically binds to a region between about amino acid residues 95 and 125 of the canine IL-31 amino acid sequence of SEQ ID NO:

32.

12. The antibody of claim 9, wherein the antibody is chimeric.

13. The antibody of claim 9, wherein the antibody is caninized or felinized.

14. The antibody of claim 9, wherein said antibody reduces, inhibits, or neutralizes an IL-31-mediated pruritic or allergic condition.

15. A method of treating an IL-31-mediated pruritic or allergic condition in a subject, comprising administering a therapeutically effective amount of the antibody of claim 14 to the subiect.

16. The method of claim 15, wherein the IL-31-mediated pruritic or allergic condition is a pruritic condition selected from the group consisting of atopic dermatitis, eczema, psoriasis, scleroderma, and pruritis.

17. The method of claim 15, wherein the IL-31-mediated pruritic or allergic condition is an allergic condition is selected from the group consisting of allergic dermatitis, summer eczema, urticaria, heaves, inflammatory airway disease, recurrent airway obstruction, airway hyper-responsiveness, chronic obstruction pulmonary disease, and inflammatory processes resulting from autoimmunity.

18. The method of claim 15, wherein the antibody is administered biweekly or monthly.

19. The method of claim 15, wherein the antibody is administered subcutaneously at 1.0 mg/kg of body weight.

20. The antibody of claim 9, wherein said antibody reduces, inhibits, or neutralizes IL-31 activity in a dog or cat.

21. A method of inhibiting IL-31 activity in a dog or cat comprising administering an antibody according to claim 20 to the dog or cat.

22. The method of claim 21, wherein the antibody is administered biweekly or monthly.

23. The method of claim 21, wherein the antibody is administered subcutaneously at 1.0 mg/kg of body weight.

24. A veterinary composition comprising a therapeutically effective amount of the antibody of claim 9.

25. A method of detecting IL-31 comprising:

(a) incubating a sample comprising IL-31 in the presence of an antibody according to claim 9; and

(b) detecting the antibody which is bound to IL-31 in the sample.

26. The method of claim 25, wherein the antibody comprises a label.

27. The method of claim 25, further comprising detecting the antibody with a second antibody comprising a label.

28. The method of claim 25, further comprising quantitating the IL-31 in the sample.